Rhythm Pharmaceuticals SG&A Expense (TTM) Insights

Rhythm Pharmaceuticals Inc (RYTM)

41.06 +0.93 (+2.32%) USD | NASDAQ | Jun 28, 16:00

41.06 0.00 (0.00%) After-Hours: 20:00

SG&A Expense (TTM) Chart

Historical SG&A Expense (TTM) Data

View and export this data back to 2017. Upgrade now.

Date	Value
March 31, 2024	127.28M
December 31, 2023	117.53M
September 30, 2023	111.47M
June 30, 2023	102.94M
March 31, 2023	95.22M
December 31, 2022	92.03M
September 30, 2022	86.71M
June 30, 2022	82.28M
March 31, 2022	75.42M
December 31, 2021	68.49M
September 30, 2021	60.61M
June 30, 2021	54.39M
March 31, 2021	47.85M
December 31, 2020	46.12M

Date	Value
September 30, 2020	42.42M
June 30, 2020	41.67M
March 31, 2020	41.59M
December 31, 2019	36.55M
September 30, 2019	35.52M
June 30, 2019	33.53M
March 31, 2019	31.12M
December 31, 2018	28.08M
September 30, 2018	24.02M
June 30, 2018	17.80M
March 31, 2018	12.72M
December 31, 2017	9.518M
September 30, 2017	7.932M
June 30, 2017	6.599M

SG&A Expense Definition

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (TTM) Range, Past 5 Years

35.52M

Minimum

Sep 2019

127.28M

Maximum

Mar 2024

71.90M

Average

68.49M

Median

Dec 2021

SG&A Expense (TTM) Benchmarks